Nice write up from TDTD Investment Conclusion We have increased our target price to C$10.50 (from C$10.00) due to the acquisition of CRH Medical as well as a modest improvement in peer-group valuations. We believe that the recent share-price weakness has created an attractive buying opportunity, particularly given that it has just closed the highly accretive and strategic acquisition of CRH that positions it well to continue its active M&A strategy and pursue a potential U.S. IPO later this year.